PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAlvimopan
Alvimopan
Alvimopan (alvimopan) is a small molecule pharmaceutical. Alvimopan was first approved as Entereg on 2008-05-20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Alvimopan (discontinued: Entereg)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alvimopan
Tradename
Company
Number
Date
Products
ENTEREGCubist PharmaceuticalsN-021775 DISCN2008-05-20
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
alvimopanANDA2024-02-08
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Alvimopan, Entereg, Cubist Pharms
89462622030-02-12U-1655
ATC Codes
A: Alimentary tract and metabolism drugs
— A06: Drugs for constipation
— A06A: Drugs for constipation
— A06AH: Peripheral opioid receptor antagonists
— A06AH02: Alvimopan
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
IleusD045823———153312
Gastrointestinal diseasesD005767———231—6
ConstipationD003248HP_0002019K59.0—231—6
Acute painD059787—R52———1—1
Postoperative painD010149—G89.18———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intestinal diseasesD007410HP_0002242K63.9—27——9
Urinary bladder neoplasmsD001749—C67——2——2
Ovarian neoplasmsD010051EFO_0003893C56——1——1
Fallopian tube neoplasmsD005185————1——1
Peritoneal neoplasmsD010534————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80—2———2
Cancer painD000072716—G89.3—1———1
Opioid-induced constipationD000079689———1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute abdomenD000006—R10.0————11
Ventral herniaD006555EFO_1001866K43————11
HerniaD006547HP_0100790K40-K46————11
Spinal fusionD013123——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlvimopan
INNalvimopan
Description
Alvimopan is a peptide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Identifiers
PDB—
CAS-ID156053-89-3
RxCUI1516803
ChEMBL IDCHEMBL270190
ChEBI ID—
PubChem CID5488548
DrugBankDB06274
UNII IDQ153V49P3Z (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 592 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alvimopan
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
304 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use